The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa

Gaedcke, Jochen; Grade, Marian; Camps, Jordi; Søkilde, Rolf; Kaczkowski, Bogumił; Schetter, Aaron J.; Difilippantonio, Michael J.; Harris, Curtis C.; Ghadimi, B. Michael; Möller, Sören; Beißbarth, Tim; Ried, Thomas; Litman, Thomas

doi:10.1158/1078-0432.ccr-12-0016

Cited by 171 publications

(163 citation statements)

References 48 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…Our observations explain why miR-135b upregulation is consistently observed in human and mouse CRC (Nagel et al, 2008;Gaedcke et al, 2012), making this miR a robust and reproducible biomarker. Our findings complement those of a recent report that identifies miR-135b as one of the most upregulated miRs in Apc min/+ mice (Necela et al, 2011), suggesting that miR-135b deregulation is independent of the specific Apc mutation or site of inactivation.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

Valeri¹,

Braconi²,

Gasparini³

et al. 2013

The Lancet

View full text Add to dashboard Cite

SUMMARYMicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.

show abstract

Section: Discussionmentioning

confidence: 52%

“…We analyzed 454 sporadic and 31 inflammatory bowel disease (IBD)-associated CRCs to confirm miR-135b upregulation previously reported in smaller CRC cohorts (Necela et al, 2011;Nagel et al, 2008;Gaedcke et al, 2012). A first set including 62 sporadic CRCs was analyzed for miR-135b expression by RT-PCR.…”

Section: Mir-135b Is Overexpressed In Human Crcmentioning

confidence: 98%

microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

Valeri¹,

Braconi²,

Gasparini³

et al. 2013

The Lancet

View full text Add to dashboard Cite

show abstract

“…miR-652 has been demonstrated to identify stage I-II breast cancer patients and to correlate with TP53, suggesting a potential role for this miRNA as prognostic biomarker (20). While the biological role of miR-652 has not been clarified in breast cancer yet, there is evidence that demonstrates the oncogenic properties of this miRNA in other cancer types (21)(22)(23). Finally, ER has been found to be a direct target of miR-18b.…”

Section: Discussionmentioning

confidence: 99%

A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients

Sahlberg

Bottai

Naume

et al. 2015

Clinical Cancer Research

191

View full text Add to dashboard Cite

Purpose: Triple-negative breast cancers (TNBC) are associated with high risk of early tumor recurrence and poor outcome. Common prognostic biomarkers give very restricted predictive information of tumor recurrences in TNBC. Human serum contains stably expressed microRNAs (miRNAs), which have been discovered to predict prognosis in patients with cancer. The purpose of this study was to identify circulating biomarkers able to predict clinical outcome in TNBC.Experimental Design: We performed genome-wide serum miRNA expression and real-time PCR analyses to investigate the ability of miRNAs in predicting tumor relapse in serum samples from 60 primary TNBC. Patients were divided into training and testing cohorts.Results: By Cox regression analysis, we identified a four-miRNA signature (miR-18b, miR-103, miR-107, and miR-652) that predicted tumor relapse and overall survival. This miRNA signature was further validated in an independent cohort of 70 TNBC. A high-risk signature score was developed and significantly associated with tumor recurrence and reduced survival. Multivariate Cox regression models indicated that the risk score based on the four-miRNA signature was an independent prognostic classifier of patients with TNBC.Conclusions: This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.

show abstract

“…miR-144 has been revealed to be involved in multiple types of human malignancy (4,5). In addition, miR-144 was reported to act as a tumor suppressor in certain types of cancer, including bladder (4), non-small cell lung (6) and colorectal (7) cancer.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells

Huang

Shi

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) have been demonstrated to be associated with multiple processes in the development and progression of human malignancies. Previous studies have observed aberrant downregulation of miR-144 in several types of cancer, including osteosarcoma. However, the function of miR-144 and the underlying mechanism in osteosarcoma remain to be elucidated. The present study indicated that miR-144 was markedly downregulated in osteosarcoma tissues and cell lines compared with that in the normal controls. Restoration of miR-144 significantly inhibited cell proliferation, migration and invasion of MG-63 osteosarcoma cells. In addition, Rho-associated coiled-coil containing protein kinase 1 (ROCK1) was identified as a novel target of miR-144 in MG-63 osteosarcoma cells. Furthermore, knockdown of ROCK1 suppressed the proliferation, migration and invasion of MG-63 osteosarcoma cells to a similar extent to the effects of miR-144 overexpression. In addition, the mRNA expression of ROCK1 was increased in osteosarcoma tissues and was negatively correlated with the expression of miR-144. In conclusion, the results of the present study suggested that miR-144 acts as a tumor suppressor by targeting ROCK1 in osteosarcoma.

show abstract

The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa

Cited by 171 publications

References 48 publications

microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients

MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells

Contact Info

Product

Resources

About